Precede Biosciences
@Precede_Bio
Followers
103
Following
21
Media
32
Statuses
36
Precede Bio is impacting precision medicine with a first-in-class liquid biopsy platform, redefining what can be learned from a simple🩸blood draw.
Boston, MA
Joined July 2023
@Precede_Bio is excited to share data at #ESMO24 demonstrating our unique platform’s capability to reveal tumor PSMA expression from a simple blood test that is highly correlated with PSMA-PET imaging. View press release: https://t.co/r2RjkIYenI
#PrecisionMedicine #Healthcare
0
1
3
Check out the latest publication from @Precede_Bio's scientific co-founders and Scientific Advisory Board members, Drs. Matthew Freedman, @DrChoueiri and @SylvanBacaLab, published in Cell Reports highlighting the potential of comprehensive epigenomics to impact therapeutic
0
0
1
@Precede_Bio is pleased to announce the newest member of our Scientific Advisory Board, Doron Lipson. Dr. Lipson is truly a visionary leader and we are grateful to benefit from his many decades of leadership in genomic application development to advance our comprehensive
0
0
1
Please join us in welcoming Josephine N. Harada to the @Precede_Bio leadership team. Josephine will be spearheading corporate and business development efforts for our novel comprehensive epigenomic #LiquidBiopsy platform. Welcome to the team, Josephine!
0
0
0
Today is Boston's Pride celebration, a day in which our hometown celebrates the rich diversity and culture of the LGBTQ+ community. At @Precede_Bio, we strive to build a diverse and inclusive workplace that honors and values each of our team members. This Pride month, we
0
0
0
Watch @Precede_Bio's Jonathan Beagan summarize the data on our comprehensive epigenomic #LiquidBiopsy platform's ability to predict ER IHC status and quantify ER signaling pathway activity in breast cancer patients from 1 mL of plasma. View data: https://t.co/5oYgq4Qdmc
0
1
0
@Precede_Bio is excited to share #ASCO24 scientific poster presentations demonstrating accurate HER2 status detection across multiple cancers and the ability to quantify ER pathway activation in breast cancer, all from a simple blood test. View press release:
0
0
0
Watch as Anthony D'Ippolito goes Behind the Science at #ASCO24 to describe how @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform can predict HER2 status and pathway activity across cancers from 1 mL of plasma. View data: https://t.co/9jduOhpYip
#OncoAlert
0
0
0
#ASCO24 starts today! Check out the latest data showing how @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform accurately predicted HER2 status for patients with breast, gastroesophageal, and ovarian cancers and ER-status and ER pathway activation for patients with
0
0
1
#ASCO24 abstracts are now available. Check out @Precede_Bio's exciting new scientific presentations for our comprehensive epigenomic #LiquidBiopsy platform. View abstracts 3047 and 1066 at https://t.co/rZuy6D8qIR
#PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment
0
0
1
We are excited to announce that two abstracts for @Precede_Bio's comprehensive epigenomic liquid biopsy platform have been selected for presentation at #ASCO24, taking place from May 31-June 4, 2024 in Chicago. #PrecisionMedicine #PrecisionOncology #Healthcare #DrugDevelopment
0
0
2
Today @Precede_Bio is excited to share three scientific poster presentations from #AACR24 for our unique, comprehensive epigenomic #LiquidBiopsy platform. #PrecisionMedicine #Healthcare #DrugDevelopment #ADCs View press release: https://t.co/jyqJsixObK
0
0
2
Juliann Chmielecki, PhD, summarizes key takeaways for @Precede_Bio's comprehensive epigenomic #LiquidBiopsy platform’s ability to reveal disease biology and therapeutic targets in #LungCancer. View data: https://t.co/mZKT6IiDAa
0
0
1
It was a busy day for @Precede_Bio at our #AACR24 poster today. Great engagement and discussion. If you haven’t seen what we are up to, we have two more to go…come visit the team - @corrie_painter, Jonathan Beagan, Jamey Guess - on April 9 to see our data in GEA cancer and
0
1
3
Today, @Precede_Bio launched our #BehindtheScience video series at #AACR24. Watch Matthew Eaton, PhD, describe key takeaways for the proof-of-concept study for our comprehensive epigenomic #LiquidBiopsy platform. View data: https://t.co/JBJkXM2nCX
0
0
2
#AACR24 starts today! Come meet the @Precede_Bio team - Carl Barrett, Jonathan Beagan, Jamey Guess, Corrie Painter, Rehan Verjee - during our upcoming presentations and learn how our comprehensive epigenomic #LiquidBiopsy platform informs on actionable drug targets, pathways, and
0
0
3
@Precede_Bio is excited to share a new interview with our CEO and co-founder, Rehan Verjee: “Unlocking Liquid Biopsy’s Full Potential ” – it’s a great primer on the capabilities of our comprehensive epigenomic #LiquidBiopsy platform as we countdown to #AACR24. View article:
0
0
2
Congratulations to Professor Matthew Freedman, one of our Precede Bio founders, for being named as the David Goldstein Chair at Dana-Farber, a newly endowed chair in support of kidney cancer research. We can think of no one more deserving of this opportunity to continue to
0
0
2
On this #InternationalWomensDay, Precede is proud to celebrate our amazing #women. Each of you brings such unique experience and capabilities to the team while all sharing the curiosity, passion and grit necessary for success in a transformational startup. We are privileged to be
0
0
1